North Star Investment Management Corp. increased its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 66,388 shares of the company’s stock after purchasing an additional 408 shares during the period. Johnson & Johnson accounts for 1.0% of North Star Investment Management Corp.’s portfolio, making the stock its 19th largest position. North Star Investment Management Corp.’s holdings in Johnson & Johnson were worth $11,727,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also recently added to or reduced their stakes in the company. Lincoln Capital Corp raised its holdings in shares of Johnson & Johnson by 15.9% during the third quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock valued at $218,000 after buying an additional 183 shares during the last quarter. Ieq Capital LLC raised its stake in Johnson & Johnson by 5.1% during the 3rd quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock valued at $20,912,000 after acquiring an additional 6,154 shares in the last quarter. RFG Advisory LLC boosted its position in Johnson & Johnson by 2.7% during the 3rd quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock worth $3,900,000 after acquiring an additional 594 shares during the period. FDx Advisors Inc. increased its holdings in shares of Johnson & Johnson by 0.3% during the third quarter. FDx Advisors Inc. now owns 50,421 shares of the company’s stock valued at $8,237,000 after purchasing an additional 153 shares during the period. Finally, HM Payson & Co. lifted its holdings in Johnson & Johnson by 3.2% in the third quarter. HM Payson & Co. now owns 783,538 shares of the company’s stock worth $127,999,000 after purchasing an additional 24,188 shares during the period. 67.94% of the stock is currently owned by institutional investors.
Johnson & Johnson Stock Up 1.0 %
JNJ stock opened at $153.89 on Tuesday. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77. The firm has a market capitalization of $400.77 billion, a P/E ratio of 22.83, a P/E/G ratio of 2.63 and a beta of 0.54. Johnson & Johnson has a 52-week low of $150.71 and a 52-week high of $186.69. The company’s 50 day simple moving average is $161.53 and its 200-day simple moving average is $167.88.
Johnson & Johnson Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were issued a $1.13 dividend. The ex-dividend date was Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.94%. Johnson & Johnson’s dividend payout ratio is 67.06%.
Insider Transactions at Johnson & Johnson
In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.35% of the stock is owned by insiders.
Analyst Ratings Changes
JNJ has been the topic of several research analyst reports. Guggenheim initiated coverage on shares of Johnson & Johnson in a research note on Tuesday, February 28th. They set a “neutral” rating and a $161.00 target price on the stock. Piper Sandler cut their target price on Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. Atlantic Securities lifted their price target on Johnson & Johnson from $160.00 to $168.00 and gave the company a “neutral” rating in a research report on Wednesday, January 25th. SVB Leerink cut their price objective on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday, January 20th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $174.73.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- First Republic Bank Hits New Low, Dimon Pushes for More Cash
- Mullen Automotive: Investment? No. Compelling Speculation, Yes
- GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
- General Mills Retreats To Buy Zone Ahead Of Earnings
- Foot Locker: Slow And Steady Wins The Race
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
